Chimeric antigen receptor T-cell therapy for central nervous system lymphoma secondary to marginal zone B-cell lymphoma: report of 1 case and review of literature
10.3760/cma.j.cn115356-20250116-00009
- VernacularTitle:CAR-T细胞治疗边缘区B细胞淋巴瘤继发中枢神经系统淋巴瘤1例并文献复习
- Author:
Zihan JIANG
1
;
Yanqing ZHANG
Author Information
1. 南方医科大学深圳医院 南方医科大学深圳临床医学院，深圳 518100
- Keywords:
Lymphoma, B-cell, marginal zone;
Central nervous system neoplasms;
Chimeric antigen receptor T cell;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2025;34(10):613-617
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of chimeric antigen receptor T (CAR-T) cell therapy for central nervous system lymphoma (CNSL) secondary to marginal zone B-cell lymphoma (MZBCL).Methods:The clinical data of a patient with CNSL secondary to MZBCL admitted to Shenzhen Hospital of Southern Medical University in September 2023 were retrospectively analyzed, and the relevant literatures were reviewed.Results:The patient was a 48-year-old male. Due to progressive swelling of the lymph nodes in the neck, lymph node resection and biopsy were performed. And then he was diagnosed as MZBCL and received R-CHOP-like regimen. The patient showed face abnormalities after treatment. The secondary CNSL was confirmed by nuclear magnetic resonance, PET-CT, and cerebrospinal fluid immunophenotyping. Despite treatment with methotrexate, Bruton tyrosine kinase inhibitors and temozolomide, the patient's disease condition progressed. Salvage treatment with CAR-T was successful, with grade 1 cytokine release syndrome and no occurrence of immune effector cell-associated neurotoxicity syndrome; complete remission was finally achieved. Follow-up until January 2025, no recurrence was found in the patient.Conclusions:CAR-T cell therapy can significantly improve the prognosis of patients with relapsed/refractory secondary CNSL, demonstrating a good efficacy and a manageable safety. However, large-scale prospective studies are still needed to evaluate long-term efficacy.
